Paloma Sosa-Fajardo

Background: Concurrent chemoradiotherapy (cCRT) followed by 1 year of consolidation durvalumab remains the standard of care for unresectable stage III non-small cell lung cancer (NSCLC), yet long-term survival is still limited and around 20% of patients present locoregional relapse. Hypofractionation may improve the therapeutic ratio by increasing the biologically effective dose (BED), shortening overall treatment time (OTT) and potentially mitigating radiation-induced lymphopenia. Objective: To identify which patients with unresectable stage II–III NSCLC may benefit most from radical-intent hypofractionated radiotherapy (HypoRT), with or without systemic therapy, and to define the technical aspects, contouring margins, and dosimetric requirements necessary for the safe use of hypofractionated schedule. Methods: A systematic search of PubMed, EMBASE, CENTRAL and Web of Science (January 2010–January 2024, English language) was performed following PRISMA principles. Eligible studies included unresectable NSCLC treated with a BED10 > 40 Gy, allowing induction systemic or targeted therapy; reviews were included for context. Records were screened by six independent reviewers. Studies were classified as non-photon vs. photon, and photon studies were further divided into non-concurrent and concurrent strategies. Clinical outcomes (dose, fractionation, biologically effective Dose for alpha/beta:10 (BED10), equivalent dose of 2 Gy/fraction (EQD2), overall treatment time (OTT), follow-up (FU), median progression-free survival (mPFS), median Overall Survival (mOS), local control (LC), grade ≥ 3 toxicity (G3) and technical variables (immobilization, simulation, GTV imaging, CTV/PTV margins, delivery, image-guided radiotherapy (IGRT), organ at risk (OAR) constraints) were extracted. Results: Of 340 records (170 duplicates), 26 studies including stage II–III disease were analyzed (1155 patients): 1 prospective cohort, 5 phase I, 12 phase II, 1 phase III and 2 phase I/II dose-escalation trials, 2 carbon-ion and 3 proton series. Of these, 13 were photon-based studies with contemporary simulation techniques. Two clinically distinct scenarios emerged. Group A (non-concurrent platinum-based strategies; 166 patients with modern 4DCT simulation) showed wide variability, ranging from a simultaneous-integrated-boost regimen to 75 Gy with 0% grade ≥ 3 toxicity and mPFS 40 months to a chemotherapy-driven schedule with 70% grade 4 chemo-related toxicity. Only one phase III trial was identified, reporting a 2-year local control of 85.8%. Group B (concurrent strategies; nine of the 14 platinum-based studies retrieved, namely those using modern simulation techniques) achieved a median BED of 89.7 Gy to the highest dose-volume, median of OS 20 months and toxicity GIII ≥ ranging 10–20%, with a median study-level grade 5 toxicity of 5.5% (range 0–17.8%; 34 fatal events among 431 evaluable patients, 7.9%), rising to 20.8% (11/53) in the most escalated randomized arm and 22.2% (2/9) in the highest dose-escalation cohort; adaptive SABR boost to 70 Gy/15 fr delivered high local control but clinically meaningful fatal toxicity. Fatal toxicity was confined to schedules exceeding BED10 100 Gy delivered to the whole tumor volume with concurrent platinum, whereas an equivalent BED restricted to a metabolically defined subvolume without concurrent chemotherapy produced no grade ≥3 events. Conclusions: Radical-intent hypofractionation is feasible across both unfit and fit unresectable stage II–III NSCLC populations, but the randomized evidence remains scarce and heterogeneous. Benefit appears most consistent when high BED is delivered with strict normal-tissue sparing in carefully selected patients using modern 4DCT-based simulation, IGRT and intensity-modulated delivery. The pattern of fatal toxicity with aggressive concurrent systemic treatments and dose escalation schedules argues for caution and for prospective trials with harmonized minimum technical standards.

Objective: We aimed to provide real-world insights into the management of non-small cell lung cancer stage III (NSCLC-SIII) in Spain. Methods: The GOECP-SEOR group conducted an observational, retrospective, multicenter study in which data from patients diagnosed with NSCLC-SIII treated in Spanish radiotherapy departments (RTDs) were collected. Results: A total of 1505 NSCLC-SIII patients from 35 RTDs from 2018 to 2021 were recruited. A total of 871 patients (57.9%) received concurrent chemoradiotherapy (cCRT), and 390 patients (25.91%) received maintenance durvalumab. The immunotherapy (IT) was well tolerated, with Common Terminology Criteria for Adverse Events (CTCAE) Grade 0–2 toxicity observed in 85% of the patients (295 patients). The median overall survival (OS) was 26 months (95% CI 9.4-Not Reached NR). There was a statistically significant difference when patients were stratified by IT, with a median OS of 40 months (95% CI 22.1-NR) in the IT maintenance cohort compared with 19.4 months (95% CI 7.1–58.1) in the non-IT cohort. Differences were also noted in progression-free survival (PFS), with a median PFS of 20.8 months (95% CI 9.6-NR) in the IT cohort versus 8.4 months (95% CI 3.1–25.1) in the non-IT cohort. These differences remained significant according to the multivariate model (OS: HR 0.45 [95% CI 0.36–0.56], p < 0.001; PFS: HR 0.5 [95% CI 0.42–0.59], p < 0.001). Conclusions: The management of NSCLC-SIII patients can vary, leading to differences in treatment outcomes. The treatment of lung cancer in NSCLC-SIII patients in RTDs across Spain aligns with international guidelines and expert recommendations.

At present, surgery is still the gold standard for the local treatment of renal cancer. Nonetheless, in several clinical scenarios, stereotactic body radiation therapy (SBRT) also known as stereotactic ablative body radiotherapy (SABR) is emerging as a highly effective ablative technique in fragile patients and those with significant comorbidities, as well as in cases where percutaneous therapy (cryoablation or radiofrequency) is not viable. However, considering the intrinsic radioresistance of renal tumors, the optimal treatment schemes have not been established. In oligometastatic patients, it has been reported that the control of the oligometastases can be a potentially curable approach. Being a technique than can be administered exclusively or in combination with systemic therapy, treatment individualization based on patient characteristics is key. Another scenario under investigation is oligoprogression, where SBRT offers the possibility of delaying further lines of systemic therapy by eliminating subclones of resistant tumor with ablative doses, with the additional opportunity of stimulating the immune system (immunomodulatory role). In this review, we have conducted an analysis of recently published studies that test the role of this technique in different clinical scenarios of this disease. We have found promising results that make SBRT a potent therapeutic approach with low toxicity. We also comment on ongoing studies that will generate the necessary evidence needed for the implementation of this technique in our daily clinical practice.